Now that CytomX Therapeutics Inc’s volume has hit 3.13 million, investors get a glimpse of its size.

A new trading day began on Monday, with CytomX Therapeutics Inc (NASDAQ: CTMX) stock price down -5.28% from the previous day of trading, before settling in for the closing price of $2.65. CTMX’s price has ranged from $0.40 to $2.71 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Annual sales at Healthcare sector company grew by 19.16% over the past five years. Meanwhile, its annual earnings per share averaged -124.50%. With a float of $131.09 million, this company’s outstanding shares have now reached $157.54 million.

Let’s look at the performance matrix of the company that is accounted for 121 employees. In terms of profitability, gross margin is 64.9%, operating margin of 24.37%, and the pretax margin is 28.35%.

CytomX Therapeutics Inc (CTMX) Insider Updates

As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of CytomX Therapeutics Inc is 16.79%, while institutional ownership is 35.39%. The most recent insider transaction that took place on Mar 18 ’25, was worth 22,556. In this transaction CEO of this company sold 37,656 shares at a rate of $0.60, taking the stock ownership to the 995,195 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Financial Officer sold 8,551 for $0.60, making the entire transaction worth $5,122. This insider now owns 201,026 shares in total.

CytomX Therapeutics Inc (CTMX) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.07 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -124.50% per share during the next fiscal year.

CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators

Here are CytomX Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.68.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.50, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.41 in one year’s time.

Technical Analysis of CytomX Therapeutics Inc (CTMX)

CytomX Therapeutics Inc (NASDAQ: CTMX) saw its 5-day average volume 3.91 million, a positive change from its year-to-date volume of 3.63 million. As of the previous 9 days, the stock’s Stochastic %D was 79.34%. Additionally, its Average True Range was 0.27.

During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 87.19%, which indicates a significant increase from 67.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 126.43% in the past 14 days, which was lower than the 168.50% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.15, while its 200-day Moving Average is $1.04. Nevertheless, the first resistance level for the watch stands at $2.74 in the near term. At $2.96, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.11. If the price goes on to break the first support level at $2.37, it is likely to go to the next support level at $2.22. Assuming the price breaks the second support level, the third support level stands at $2.00.

CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats

With a market capitalization of 395.44 million, the company has a total of 80,621K Shares Outstanding. Currently, annual sales are 138,100 K while annual income is 31,870 K. The company’s previous quarter sales were 50,920 K while its latest quarter income was 23,530 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.